Evidence map›Paper›PMID 38826439›Full record

ArticlebioRxiv : the preprint server for biology2024

KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development.

Samantha L Tinsley, Rebecca A Shelley, Gaganpreet K Mall, Ella Rose D Chianis, Alisha Dhiman, Garima Baral, Harish Kothandaraman, Mary C Thoma, Colin J Daniel, Nadia Atallah Lanman and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Samantha L TinsleyPurdue University Interdisciplinary Life Sciences Program (PULSe), Purdue University, West Lafayette, IN, USA.ORCID 0000-0002-8761-5504
Rebecca A ShelleyDepartment of Biological Sciences, Purdue University, West Lafayette, IN USA.
Gaganpreet K MallDepartment of Biological Sciences, Purdue University, West Lafayette, IN USA.
Ella Rose D ChianisDepartment of Biological Sciences, Purdue University, West Lafayette, IN USA.
Alisha DhimanDepartment of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA.ORCID 0000-0002-4395-9292
Garima BaralDepartment of Biological Sciences, Purdue University, West Lafayette, IN USA.
Harish KothandaramanPurdue Institute for Cancer Research, Purdue University, West Lafayette, IN, USA.
Mary C ThomaDepartment of Molecular Medicine and Genetics, Oregon Health and Sciences University, Portland, Oregon, USA.
Colin J DanielDepartment of Molecular Medicine and Genetics, Oregon Health and Sciences University, Portland, Oregon, USA.
Nadia Atallah LanmanPurdue Institute for Cancer Research, Purdue University, West Lafayette, IN, USA.
Marina Pasca di MaglianoUniversity of Michigan School of Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-9632-9035
Goutham NarlaUniversity of Michigan School of Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0003-4098-4203
Luis SolorioWeldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA.
Emily C DykhuizenPurdue University Interdisciplinary Life Sciences Program (PULSe), Purdue University, West Lafayette, IN, USA.ORCID 0000-0003-3072-1469
Rosalie C SearsDepartment of Molecular Medicine and Genetics, Oregon Health and Sciences University, Portland, Oregon, USA.ORCID 0000-0003-1558-2413
Brittany L Allen-PetersenPurdue University Interdisciplinary Life Sciences Program (PULSe), Purdue University, West Lafayette, IN, USA.ORCID 0000-0002-7436-9412

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4M
Hydroxylation regulation of c-MycR01CA186241 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mu-Shui Dai, ROSALIE C SEARS · 2015 to 2026
$4.2M
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimensU01CA224012 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, COUSSENS, LISA M. · 2019 to 2023
$2.9M
The role of PP2A B56a in pancreatic tumorigenesisK22CA237620 · NCI · PURDUE UNIVERSITY · PI ALLEN-PETERSEN, BRITTANY · 2020 to 2022
$525k
NCI NIH HHS K22 CA237620NCI NIH HHS P30 CA023168NCI NIH HHS R01 CA186241NCI NIH HHS U01 CA224012
6 · The paper itself

Abstract

Oncogenic mutations in KRAS are present in approximately 95% of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) and are considered the initiating event of pancreatic intraepithelial neoplasia (PanIN) precursor lesions. While it is well established that KRAS mutations drive the activation of oncogenic kinase cascades during pancreatic oncogenesis, the effects of oncogenic KRAS signaling on regulation of phosphatases during this process is not fully appreciated. Protein Phosphatase 2A (PP2A) has been implicated in suppressing KRAS-driven cellular transformation. However, low PP2A activity is observed in PDAC cells compared to non-transformed cells, suggesting that suppression of PP2A activity is an important step in the overall development of PDAC. In the current study, we demonstrate that KRAS

Indexed as

ADMCIP2AKRASPDACPP2A

Identifiers

PMID38826439
PMCPMC11142131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.